Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments. Cancer resistance continues to be one of the most daunting challenges facing patients, clinicians and researchers in oncology today. At ORIC, our resistance platform is focused on three areas:
Our lead product candidate, ORIC-101, is currently in two separate Phase 1b trials. GR is overexpressed in multiple solid tumors, is thought to enable bypass resistance and is associated with poorer outcomes; thus, blocking its activity could have far-reaching effects.
We’re currently conducting two separate Phase 1b clinical trials of ORIC-101 in combination with: (1) Xtandi® (enzalutamide) in metastatic prostate cancer and (2) Abraxane® (nab-paclitaxel) in advanced or metastatic solid tumors. Do you qualify?
Our collaborative, open culture gives each of us the authority, responsibility and support to do cutting-edge work on therapies for treatment-resistant cancers.